A Phase 1, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Single and Multiple Ascending Doses of FB704A
Latest Information Update: 23 Jul 2020
Price :
$35 *
At a glance
- Drugs FB 704A (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Fountain BioPharma
- 17 Jul 2020 Status changed from recruiting to completed.
- 29 Mar 2019 New trial record